A minimally invasive endoscopic "gut resurfacing" procedure on the upper small intestine is showing early promise for people coming off GLP-1 weight loss drugs. In the REMAIN-1 midpoint cohort, participants who received duodenal mucosal resurfacing kept more than 80% of the weight they had lost on medication and regained about 7 pounds on average, while those who underwent a sham procedure put substantially more weight back on. The interim data were released ahead of a scheduled presentation at Digestive Disease Week in Chicago on May 4, 2026.
Midpoint cohort: randomized, blinded and promising
As reported by ScienceDaily, the midpoint analysis included 45 adults in a randomized, blinded trial, with 29 assigned to the Revita duodenal mucosal resurfacing procedure and 16 to a sham procedure. All had lost at least 15% of their body weight on tirzepatide before stopping the drug. Reuters reported that by six months, people in the sham arm had regained roughly 40% more weight than those who received the active treatment.
How the "gut reset" works
Duodenal mucosal resurfacing uses controlled hydrothermal energy to remove a thin layer of the duodenal lining so that healthier mucosa can grow back, a process researchers say may help reset how the gut senses nutrients and sends metabolic signals. In a fact sheet and training materials, Fractyl Health lays out the Revita system and the step-by-step procedure. The company and prior clinical reports tie the effect to changes in hormone production in the upper small intestine rather than any ongoing exposure to GLP-1 drugs.
Why clinicians are watching
"Finding a treatment that allows patients to stop these medications without weight regain is a huge unmet need," lead investigator Shelby Sullivan said in a DDW news release. EurekAlert notes that the REMAIN-1 program is fully enrolled across multiple sites and that topline six-month pivotal data are expected in early Q4 2026, with a planned marketing submission later that year. If the larger cohort confirms the early signal, researchers say the approach could offer a non-drug option for people who cannot, or prefer not to, remain on long-term GLP-1 therapy.
Regulatory status and safety
The Revita system already has a CE mark in Europe and has been used commercially in Germany, but it is still considered investigational in the United States, according to the company. Fractyl's SEC filings and the REMAIN-1 registry entry at ClinicalTrials.gov describe the staged trial design and indicate that the randomized pivotal cohort is expected to include about 315 participants. No serious device-related complications were reported in the small midpoint cohort, although investigators caution that the results are interim and that the full data set will be needed to judge long-term durability and safety.
What this means for patients
Fractyl Health, based in the Boston area, has positioned Revita as a post-GLP-1 weight maintenance option while it advances United States trials and regulatory filings. Until the pivotal results are in, experts say patients and clinicians should treat these midpoint findings as hypothesis-generating rather than practice-changing and should carefully weigh potential risks, benefits and costs when considering a new procedural approach.
